202 related articles for article (PubMed ID: 15173512)
1. Cystic fibrosis newborn screening: shifting the key question from "should we screen?" to "how should we screen?".
Farrell PM
Pediatrics; 2004 Jun; 113(6):1811-2. PubMed ID: 15173512
[No Abstract] [Full Text] [Related]
2. Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections.
Comeau AM; Parad RB; Dorkin HL; Dovey M; Gerstle R; Haver K; Lapey A; O'Sullivan BP; Waltz DA; Zwerdling RG; Eaton RB
Pediatrics; 2004 Jun; 113(6):1573-81. PubMed ID: 15173476
[TBL] [Abstract][Full Text] [Related]
3. Risk calculations for cystic fibrosis in neonatal screening by immunoreactive trypsinogen and CFTR mutation tests.
Ogino S; Flodman P; Wilson RB; Gold B; Grody WW
Genet Med; 2005; 7(5):317-27. PubMed ID: 15915083
[TBL] [Abstract][Full Text] [Related]
4. Two-tiered immunoreactive trypsinogen-based newborn screening for cystic fibrosis in Colorado: screening efficacy and diagnostic outcomes.
Sontag MK; Hammond KB; Zielenski J; Wagener JS; Accurso FJ
J Pediatr; 2005 Sep; 147(3 Suppl):S83-8. PubMed ID: 16202790
[TBL] [Abstract][Full Text] [Related]
5. Combining immunoreactive trypsinogen and pancreatitis-associated protein assays, a method of newborn screening for cystic fibrosis that avoids DNA analysis.
Sarles J; Berthézène P; Le Louarn C; Somma C; Perini JM; Catheline M; Mirallié S; Luzet K; Roussey M; Farriaux JP; Berthelot J; Dagorn JC
J Pediatr; 2005 Sep; 147(3):302-5. PubMed ID: 16182665
[TBL] [Abstract][Full Text] [Related]
6. Improving the Sensitivity and Positive Predictive Value in a Cystic Fibrosis Newborn Screening Program Using a Repeat Immunoreactive Trypsinogen and Genetic Analysis.
Sontag MK; Lee R; Wright D; Freedenberg D; Sagel SD
J Pediatr; 2016 Aug; 175():150-158.e1. PubMed ID: 27131402
[TBL] [Abstract][Full Text] [Related]
7. Newborn screening and carrier screening for cystic fibrosis: alternative or complementary?
Castellani C; Massie J
Eur Respir J; 2014 Jan; 43(1):20-3. PubMed ID: 24381320
[No Abstract] [Full Text] [Related]
8. Diagnostic dilemmas resulting from the immunoreactive trypsinogen/DNA cystic fibrosis newborn screening algorithm.
Parad RB; Comeau AM
J Pediatr; 2005 Sep; 147(3 Suppl):S78-82. PubMed ID: 16202789
[TBL] [Abstract][Full Text] [Related]
9. The impact of newborn screening on cystic fibrosis testing in Victoria, Australia.
Balnaves ME; Bonacquisto L; Francis I; Glazner J; Forrest S
J Med Genet; 1995 Jul; 32(7):537-42. PubMed ID: 7562966
[TBL] [Abstract][Full Text] [Related]
10. Newborn cystic fibrosis screening in southeastern Mexico: Birth prevalence and novel CFTR gene variants.
Ibarra-González I; Campos-Garcia FJ; Herrera-Pérez LDA; Martínez-Cruz P; Moreno-Graciano CM; Contreras-Capetillo SN; León-Burgos V; Maldonado-Solis FA; Alcántara-Ortigoza MA; González Del Angel A; Vela-Amieva M
J Med Screen; 2018 Sep; 25(3):119-125. PubMed ID: 28992757
[TBL] [Abstract][Full Text] [Related]
11. Newborn screening for cystic fibrosis in Wisconsin: nine-year experience with routine trypsinogen/DNA testing.
Rock MJ; Hoffman G; Laessig RH; Kopish GJ; Litsheim TJ; Farrell PM
J Pediatr; 2005 Sep; 147(3 Suppl):S73-7. PubMed ID: 16202788
[TBL] [Abstract][Full Text] [Related]
12. Positive neonatal screening for cystic fibrosis in neonates with renal failure.
Oosterveld MJ; Schilperoort JV; Lilien MR; Arets HG
Thorax; 2010 Jul; 65(7):652-3. PubMed ID: 20627926
[TBL] [Abstract][Full Text] [Related]
13. False negative cystic fibrosis newborn screen.
Collaco JM; Panny SR; Hamosh A; Mogayzel PJ
Clin Pediatr (Phila); 2010 Mar; 49(3):214-6. PubMed ID: 20164071
[No Abstract] [Full Text] [Related]
14. Newborn screening for cystic fibrosis.
Hayes D
South Med J; 2006 Apr; 99(4):403. PubMed ID: 16634253
[No Abstract] [Full Text] [Related]
15. Newborn screening for cystic fibrosis.
Wallace J; Stein Q
S D Med; 2006 Oct; 59(10):429-31. PubMed ID: 17124920
[No Abstract] [Full Text] [Related]
16. Secondhand Smoke Exposure and Serum Trypsinogen in Cystic Fibrosis Carriers.
Ellery KM; Kopp B; Conwell DL; Gariepy C
Pancreas; 2019 Oct; 48(9):1155-1159. PubMed ID: 31593019
[TBL] [Abstract][Full Text] [Related]
17. Cystic fibrosis carriers have higher neonatal immunoreactive trypsinogen values than non-carriers.
Castellani C; Picci L; Scarpa M; Dechecchi MC; Zanolla L; Assael BM; Zacchello F
Am J Med Genet A; 2005 Jun; 135(2):142-4. PubMed ID: 15832355
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis of cystic fibrosis after newborn screening: the Australasian experience--twenty years and five million babies later: a consensus statement from the Australasian Paediatric Respiratory Group.
Massie J; Clements B;
Pediatr Pulmonol; 2005 May; 39(5):440-6. PubMed ID: 15704202
[TBL] [Abstract][Full Text] [Related]
19. Comparison of different IRT-PAP protocols to screen newborns for cystic fibrosis in three central European populations.
Sommerburg O; Krulisova V; Hammermann J; Lindner M; Stahl M; Muckenthaler M; Kohlmueller D; Happich M; Kulozik AE; Votava F; Balascakova M; Skalicka V; Stopsack M; Gahr M; Macek M; Mall MA; Hoffmann GF
J Cyst Fibros; 2014 Jan; 13(1):15-23. PubMed ID: 23891278
[TBL] [Abstract][Full Text] [Related]
20. A model-based economic evaluation of four newborn screening strategies for cystic fibrosis in Flanders, Belgium.
Schmidt M; Werbrouck A; Verhaeghe N; De Wachter E; Simoens S; Annemans L; Putman K
Acta Clin Belg; 2020 Jun; 75(3):212-220. PubMed ID: 31007159
[No Abstract] [Full Text] [Related]
[Next] [New Search]
